Pharmacokinetic evaluation of an oral tablet form of low-molecularweight heparin and deoxycholic acid conjugate as a novel oral anticoagulant

Thrombosis and Haemostasis

Volumn 105, Issue 6, 2011, Pages 1060-1071

  Park, Jin Woo ^a,b   Jeon, Ok Cheol ^c   Kim, Sang Kyoon ^a   Al Hilal, Taslim A ^a   Lim, Kyung Min ^b   Moon, Hyun Tae ^c   Kim, Choong Yong ^d   Byun, Youngro ^e  

^a Seoul National University   (South Korea)

^b AmorePacific Corporation   (South Korea)

^c Mediplex Corporation   (South Korea)

^d Korea Research Institute of Chemical Technology   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

Anticoagulants; Deoxycholic acid; Low molecular weight heparin; Oral delivery; Solid dosage form

Indexed keywords

DEOXYCHOLIC ACID; LABRASOL; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; POLOXAMER; RADIOISOTOPE; TYRAMINE I 131; UNCLASSIFIED DRUG; WARFARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CIRCULATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HAPLORHINI; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TABLET DISINTEGRATION; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; DEOXYCHOLIC ACID; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HAPLORHINI; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY; MALE; MICE; MICE, INBRED ICR; PROTEIN ENGINEERING; RATS; RATS, SPRAGUE-DAWLEY; TABLETS; VENOUS THROMBOSIS;

EID: 79958095877     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-07-0484     Document Type: Article

References (48)

1. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.
2. Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008; 99: 807-818.
3. Gallus AS. Anticoagulants in the prevention of venous thromboembolism. Baillieres Clin Haematol 1990; 3: 651-684.
4. Jack H, Sonia SA, Jonathan LH, et al. Guide to anticoagulant therapy: heparin. Circulation 2001; 103: 2994-3018.
5. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-194.
6. Hull RD. Treatment of pulmonary embolism: the use of low-molecular weight heparin in the inpatient and outpatient settings. Thromb Haemost 2008; 99: 502-510.
7. Amin AN, Lin J, Lenhart G, et al. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. Thromb Haemost 2009; 102: 321-326.
8. Dal Pozzo A, Acquasaliente M, Geron MR. New heparin complexes active by intestinal absorption: I-multiple ion pairs with basic organic compounds. Thromb Res 1989; 56: 119-124.
9. Malkov D, Wang HZ, Dinh S, et al. Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybezoyl) amino] caprylate. Pharm Res 2002; 19: 1180-1184.
10. Kim SK, Lee EH, Vaishali B, et al. Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates. J Control Release 2005; 105: 32-42.
11. Andersson M, Lofroth JE. Small particles of a heparin/chitosan complex prepared from a pharmaceutically acceptable microemulsion. Int J Pharm 2003; 257: 305-309.
12. Jiao Y, Ubrich N, Marchand-Arvier M, et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002; 105: 230-235.
13. Hoffart V, Lamprecht A, Maincent P, et al. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release 2006; 113: 38-42.
14. Dufresne MH, Leroux JC. Study of the micellization behavior of different order amino block copolymers with heparin. Pharm Res 2004; 21: 160-169.
15. Ueno M, Nakasaki T, Horikoshi I, et al. Oral administration of liposomally-entrapped heparin to beagle dogs. Chem Pharm Bull (Tokyo) 1982; 30: 2245-2247.
16. Hayes PY, Ross BP, Thomas BG, et al. Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin. Bioorg Med Chem 2006; 14: 143-152.
17. Ito Y, Kusawake T, Rama Prasad YV et al. Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. Int J Pharm 2006; 317: 114-119.
18. Kast CE, Guggi D, Langoth N, et al. Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm Res 2003; 20: 931-936.
19. Bernkop-Schnürch A, Kast CE, Guggi D. Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J Control Release 2003; 93: 95-103.
20. Thanou M, Nihot MT, Jansen M, et al. Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. J Pharm Sci 2001; 90: 38-46.
21. Thanou M, Henderson S, Kydonieus A, et al. N-sulfonato-N, O-carboxymethylchitosan: A novel polymeric absorption enhancer for the oral delivery of macromolecules. J Control Release 2007; 117: 171-178.
22. Windsor E, Cronheim GE. Gastrointestinal absorption of heparin and synthetic heparinoids. Naturwissenschaften 1961; 190: 263-264.
23. Rivera TM, Leone-Bay A, Paton DR, et al. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybezoyl)amino]caprylate: pharmacological considerations. Pharm Res 1997; 14: 1830-1834.
24. Gonze MD, Salartash K, Sternbergh III WC, et al. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation 2000; 101: 2658-2661.
25. Berkowitz SD, Marder VJ, Kosutic G, et al. Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective hip arthroplasty. J Thromb Haemost 2003; 1: 1914-1919.
26. Pineo G, Hull R, Marder V. Oral delivery of heparin: SNAC and related formulations. Best Pract Res Clin Haematol 2004; 17: 153-160.
27. Mousa SA, Zhang F, Aljada A, et al. Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects. J Clin Pharmacol 2007; 47: 1508-1520.
28. Lee YK, Nam JH, Shin HC, et al. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation 2001; 104: 3116-3120.
29. Kim SK, Lee DY, Kim CY, et al. A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study. J Control Release 2007; 123: 155-163.
30. Lee YK, Kim SH, Byun Y. Oral delivery of new heparin derivatives in rats. Pharm Res 2000; 17: 1259-1264.
31. Fini A, Fazio G, Roda A, et al. Basic cholane derivatives. XI: comparison between acid and basic derivatives. J Pharm Sci 1992; 81: 726-730.
32. Sundaram M, Qi Y, Shriver Z, et al. Rational design of low-molecular weight heparins with improved in vivo activity. PNAS 2003; 100: 651-656.
33. Kim SK, Lee DY, Kim C, et al. Prevention effect of orally active heparin derivative on deep vein thrombosis. Thromb Haemost 2006; 96: 149-153.
34. Zeymer U, Gitt A, Junger C, et al. Efficacy and safety of enoxaparin in unselected patients with ST segment elevation myocardial infarction. Thromb Haemost 2008; 99: 150-154.
35. De Luca G, Marino P. Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction. Thromb Haemost 2008; 100: 184-195.
36. van Doormaal FF, Raskob GE, Davidson BL, et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost 2009; 101: 762-769.
37. Traby L, Kaider A, Schmid R, et al. The effect of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. Thromb Haemost 2010; 104: 92-99.
38. Laux V, Perzborn E, Heitmeier S, et al. Direct inhibitors of coagulation proteins-the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost 2009; 102: 892-899.
39. Hiebert LM, Ping T, Wice SM. Enhanced antithrombotic effects of unfractionated heparin in rats after repeated oral doses and its relationship to endothelial heparin concentration. Br J Pharmacol 2008; 153: 1177-1184.
40. Moazed B, Hiebert LM. Movement of heparin across rat gastric mucosa is dependent on molecular weight and pH. Pharm Res 2009; 26: 189-195.
41. Javot L, Sapin A, Scala-Bertola J, et al. Oral administration of a microencapsulated low-molecular-weight heparin to rabbits: Anti-Xa and anti-IIa profiles. Thromb Haemost 2010; 103: 1254-1267.
42. Kim SK, Kim K, Lee S, et al. Evaluation of absorption of heparin-DOCA conjugates on the intestinal wall using a surface Plasmon resonance. J Pharm Biomed Anal 2005; 39: 861-870.
43. Kim SK, Lee DY, Lee EH, et al. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anticoagulant. J Control Release 2007; 120: 4-10.
44. Lee YK, Kim SK, Lee DY, et al. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. J Control Release 2006; 111: 290-298.
45. 99mTc-labelled enoxaparin in the rat: evaluation of dosimetry parameters. Biomed Pharmacother 1990; 44: 317-323.
46. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996; 26: 24-28.
47. McAllister BM, Demis DJ. Heparin metabolism: isolated and characterization of uroheparin. Nature 1966; 212: 293-294.
48. Dawes J, Pepper DS. Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-860.